Genmab Future Growth

Future criteria checks 2/6

Genmab is forecast to grow earnings and revenue by 9.6% and 10.2% per annum respectively. EPS is expected to grow by 7.8% per annum. Return on equity is forecast to be 32.3% in 3 years.

Key information

9.6%

Earnings growth rate

7.80%

EPS growth rate

Biotechs earnings growth	23.1%
Revenue growth rate	10.2%
Future return on equity	32.30%
Analyst coverage	Good
Last updated	13 Jan 2026

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGS:GMAB - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	5,752	2,060	2,820	2,413	7
12/31/2027	4,967	1,471	1,766	1,227	13
12/31/2026	4,271	998	1,397	920	14
12/31/2025	3,696	1,162	961	917	16
9/30/2025	3,846	1,583	1,294	1,369	N/A
6/30/2025	3,647	1,371	1,055	1,134	N/A
3/31/2025	3,231	1,140	1,124	1,194	N/A
12/31/2024	2,990	1,090	1,037	1,079	N/A
9/30/2024	2,964	702	980	1,005	N/A
6/30/2024	2,743	798	939	971	N/A
3/31/2024	2,576	791	775	818	N/A
12/31/2023	2,440	645	1,037	1,093	N/A
9/30/2023	2,389	590	806	866	N/A
6/30/2023	2,378	680	826	885	N/A
3/31/2023	2,216	757	902	955	N/A
12/31/2022	2,088	785	518	563	N/A
9/30/2022	1,580	745	459	495	N/A
6/30/2022	1,438	558	277	315	N/A
3/31/2022	1,342	354	201	242	N/A
12/31/2021	1,288	452	302	341	N/A
9/30/2021	1,232	448	148	185	N/A
6/30/2021	1,168	401	894	928	N/A
3/31/2021	1,703	880	856	899	N/A
12/31/2020	1,660	781	1,006	1,056	N/A
9/30/2020	1,736	889	1,122	1,166	N/A
6/30/2020	1,559	853	357	399	N/A
3/31/2020	837	349	361	383	N/A
12/31/2019	806	325	182	199	N/A
9/30/2019	532	223	183	198	N/A
6/30/2019	487	178	N/A	190	N/A
3/31/2019	441	202	N/A	180	N/A
12/31/2018	464	226	N/A	156	N/A
9/30/2018	437	222	N/A	165	N/A
6/30/2018	397	194	N/A	140	N/A
3/31/2018	462	213	N/A	215	N/A
12/31/2017	381	178	N/A	256	N/A
9/30/2017	361	184	N/A	200	N/A
6/30/2017	356	208	N/A	218	N/A
3/31/2017	272	174	N/A	156	N/A
12/31/2016	257	168	N/A	46	N/A
9/30/2016	221	111	N/A	99	N/A
6/30/2016	205	102	N/A	88	N/A
3/31/2016	183	82	N/A	55	N/A
12/31/2015	165	111	N/A	45	N/A
9/30/2015	116	66	N/A	10	N/A
6/30/2015	115	69	N/A	3	N/A
3/31/2015	102	60	N/A	14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GMAB's forecast earnings growth (9.6% per year) is above the savings rate (3.3%).

Earnings vs Market: GMAB's earnings (9.6% per year) are forecast to grow slower than the US market (16.1% per year).

High Growth Earnings: GMAB's earnings are forecast to grow, but not significantly.

Revenue vs Market: GMAB's revenue (10.2% per year) is forecast to grow slower than the US market (10.5% per year).

High Growth Revenue: GMAB's revenue (10.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: GMAB's Return on Equity is forecast to be high in 3 years time (32.3%)

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/01/14 13:14
End of Day Share Price	2026/01/14 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genmab A/S is covered by 45 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Gordon	Barclays
Xue Chen	Barclays
Emily Field	Barclays

Genmab Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Genmab Provides Earnings Guidance for the Full Year 2025

Genmab A/S Raises Earnings Guidance for the Year 2025

Genmab A/S Provides Revenue Guidance for 2025

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Provides Earnings Guidance for 2023

Recent updates

Genmab: AI Partnership And Clinical Data Fuel Growth

Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio Review

Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.

Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab A/S to Report First Half, 2026 Results on Aug 06, 2026

Genmab Provides Earnings Guidance for the Full Year 2025

Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer

Genmab Reportedly in Advanced Talks to Buy Merus

Genmab A/S Announces Updated Results from Phase 2 Epcore®? Nhl-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)

Genmab A/S Raises Earnings Guidance for the Year 2025

Genmab Announces Changes to Its Executive Committee

Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial

Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association (Eha) Congress

Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular Lymphoma

Genmab's Outlook Beyond Darzalex's Patent Cliff

Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical Cancer

Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-S

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Genmab A/S, Annual General Meeting, Mar 12, 2025

Genmab A/S Provides Revenue Guidance for 2025

Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial

Genmab Is Too Attractive To Ignore

Genmab: Looking To Manage My Position Around Q3 Earnings

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

Genmab: Strong H1 2024 Performance, Partner BioNTech Gives Up On Acasunlimab

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Genmab A/S Takes Full Control of Acasunlimab Development Program

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Genmab: A Complicated Tale

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab Acquires A Missing Piece For Its Pipeline

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab: Recent Updates Support The Growth Narrative

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Genmab: 3 Trends To Track For A Strong 2024 And Beyond

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab reports Q3 worldwide sales of $2.05B for Darzalex

Genmab improves FY 2022 guidance

Genmab reports Q2 worldwide net sales of DARZALEX $1.99B

Genmab: A Royalty Powerhouse With A Strong Pipeline

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies